Lilly Oncology President Anne White On Loxo Success, What’s To Come
New Approval And Novel BTK Drug Emerge After Cancer R&D Reconfiguration
Executive Summary
White said the late 2019 creation of Loxo Oncology at Lilly to spearhead cancer R&D has exceeded her expectations. The executive also discussed COVID-19’s impact on drug sales and cancer screening.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by Scrip's worldwide team, in this podcast version of Five Must-Know Things.
Big COVID-19-Related Sales Drive Lilly’s Strong Q4 Performance
Neutralizing antibody bamlanivimab brought in $871m during the fourth quarter, skewing already solid growth upwards. Discussion of donanemab in Alzheimer’s dominated Lilly’s quarterly call.
From China With IO: Lilly Bets $1bn+ To Take Innovent Drug Global
Lilly is acquiring exclusive global rights to a Chinese domestically developed immuno-oncology drug in one of the year’s biggest commercial deals in the country.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports